FINWIRES · TerminalLIVE
FINWIRES

尽管房地产市场持续低迷,招商银行第一季度利润仍小幅增长。

By

-- 招商银行(沪港通:600036,港交所:3968)公布第一季度利润小幅增长,尽管该行仍在应对中国房地产市场长期低迷带来的风险。 根据周三提交给香港联交所的文件,归属于股东的净利润同比增长1.5%,从上年同期的373亿元人民币增至379亿元人民币,每股收益从1.48元人民币增至1.49元人民币。 净营业收入同比增长3.9%,从上年同期的837亿元人民币增至870亿元人民币。 业绩表现平平,是因为该行仍在应对中国房地产行业的风险。截至第一季度末,招商银行表示,其房地产相关业务的信贷风险总额为3480亿元人民币,同比下降1.7%。 据彭博新闻报道,中国房地产市场已连续第五年低迷,包括北京和上海在内的主要城市的房价较峰值下跌超过三分之一。 招商银行表示,为降低风险,将“加大对‘白名单’项目的支持力度,以促进房地产市场的稳定运行和高质量发展”。 彭博行业研究估计,数百万中国房主的抵押贷款目前处于“负资产”状态,即借款人所欠贷款超过其房产的当前价值。 招商银行表示,其住房抵押贷款的整体风险“可控”,抵押品充足。该投资组合的加权平均贷款价值比为40.7%,较上年同期上升0.07个百分点。 与此同时,该集团第一季度的运营费用同比增长2.9%,达到274亿元人民币。 本季度预期信贷损失较上年同期增长16%,达到148亿元人民币。 截至本季度末,招商银行不良贷款余额同比增加16.5亿元人民币,达到699亿元人民币。不良贷款率维持在0.94%不变。 招商银行表示,截至第一季度末,其零售客户数量增长1.3%,达到2.27亿;管理资产总额较上年末增长4.5%,达到17.9万亿元人民币。 该行近期以278亿元人民币赎回了2.75亿股国内优先股,以结算这些股票的面值和应计股息。

Related Articles

Research

Research Alert: Gsk Q1 Beat As Specialty Medicines Remains Strong, Reiterates 2026 Outlook

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GSK delivered a Q1 2026 beat with sales growing 2% Y/Y (5% CER), led by Specialty Medicines (+10% or +14% CER), particularly oncology with strong Jemperli and Ojjaara uptake, while Vaccines grew 4% CER on record Shingrix sales. Core EPS grew 4% or 9% CER to GBP0.465, ahead of the consensus of GBP0.44, supported by a favorable product mix and cost control that lifted the core operating margin by 1.0%-pt or 1.8%-pts CER. We view the Q1 update positively given the beat and margin expansion, though we are mindful of currency headwinds. GSK reiterated its 2026 guidance for 3%-5% sales growth and 7%-9% core operating profit growth (CER), which is broadly aligned with that of several peers like Sanofi and Roche despite implying slower growth versus 2025. We expect revenue to be supported by key Specialty Medicines products, with GSK targeting the segment to contribute more than 50% of sales by 2031 (Q1 2026: 42%), while recent acquisitions provide a much-needed boost to growth and the drug pipeline, in our view.

$GSK
Asia

Gamuda Unit Bags Nearly MYR6 Billion Project from Sabah State Water Department

Gamuda (KLSE:GAMUDA) unit Upper Padas Power received a Letter of Acceptance worth 5.98 billion ringgit from the Sabah State Water Department for Phase 1 of the Skim Bekalan Air Ulu Padas.The project forms a bolt-on development linked to the Ulu Padas Hydroelectric Project and is designed to strengthen water supply for Sabah's west coast, according to a Wednesday Malaysian bourse filing.Phase 1 involves the construction of a 350 million litres per day water treatment plant in Beaufort, along with about 200km of pipelines stretching from Sipitang to Kota Kinabalu.The project marks a key infrastructure expansion alongside its hydroelectric development in Sabah, Malaysia, the company said.

$KLSE:GAMUDA
Equities

Aker Solutions to Develop Framed Modules Components for Rolls-Royce SMR

Aker Solutions (AKSO.OL) secured a deal to develop non-nuclear parts of framed modules for Rolls-Royce (RR.L) unit Rolls-Royce SMR, according to a Wednesday release.Under a memorandum of understanding, the Norwegian energy-focused engineering group will work with Rolls-Royce SMR to define the design and scope, and modularization approach for customer projects in the UK and other countries, with an initial focus on the UK and the Czech Republic.

$AKSO.OL$RR.L
尽管房地产市场持续低迷,招商银行第一季度利润仍小幅增长。 | FINWIRES